Literature DB >> 23528658

IFNγ in combination with IL-7 enhances immunotherapy in two rat glioma models.

Sara Fritzell1, Sofia Eberstål, Emma Sandén, Edward Visse, Anna Darabi, Peter Siesjö.   

Abstract

Peripheral immunization, using a combination of interferon-gamma (IFNγ)- and interleukin-7 (IL-7)-producing tumor cells, eradicated 75% of pre-established intracerebral N32 rat glioma tumors, and prolonged survival in the more aggressive RG2 model. Rats immunized with IFNγ- and IL7-transduced N32 cells displayed increases in IFNγ plasma levels and proliferating circulating T cells when compared with rats immunized with N32-wild type cells. Following irradiation, the expression of MHC I and II was high on N32-IFNγ cells, but low on RG2-IFNγ cells. In conclusion, IFNγ and IL-7 immunizations prolong survival in two rat glioma models.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23528658     DOI： 10.1016/j.jneuroim.2013.02.017

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  13 in total

Review 1.  Concepts of immunotherapy for glioma.

Authors:  Mira A Patel; Drew M Pardoll
Journal:  J Neurooncol       Date:  2015-06-13       Impact factor: 4.130

Review 2.  Common gamma chain cytokines in combinatorial immune strategies against cancer.

Authors:  Stephanie R Pulliam; Roman V Uzhachenko; Samuel E Adunyah; Anil Shanker
Journal:  Immunol Lett       Date:  2015-11-17       Impact factor: 3.685

Review 3.  Stem cell-based therapies for tumors in the brain: are we there yet?

Authors:  Khalid Shah
Journal:  Neuro Oncol       Date:  2016-06-09       Impact factor: 12.300

4.  A standardized and reproducible protocol for serum-free monolayer culturing of primary paediatric brain tumours to be utilized for therapeutic assays.

Authors:  Emma Sandén; Sofia Eberstål; Edward Visse; Peter Siesjö; Anna Darabi
Journal:  Sci Rep       Date:  2015-07-17       Impact factor: 4.379

Review 5.  Interleukin-7 and interleukin-15 for cancer.

Authors:  Paul Zarogoulidis; Sofia Lampaki; Lonny Yarmus; Ioannis Kioumis; Georgia Pitsiou; Nikolaos Katsikogiannis; Wolfgang Hohenforst-Schmidt; Qiang Li; Haidong Huang; Antonios Sakkas; John Organtzis; Leonidas Sakkas; Ioannis Mpoukovinas; Kosmas Tsakiridis; George Lazaridis; Konstantinos Syrigos; Konstantinos Zarogoulidis
Journal:  J Cancer       Date:  2014-10-22       Impact factor: 4.207

6.  ALA-PpIX mediated photodynamic therapy of malignant gliomas augmented by hypothermia.

Authors:  Carl J Fisher; Carolyn Niu; Warren Foltz; Yonghong Chen; Elena Sidorova-Darmos; James H Eubanks; Lothar Lilge
Journal:  PLoS One       Date:  2017-07-31       Impact factor: 3.240

7.  Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer.

Authors:  Anqi Lin; Zhengang Qiu; Jian Zhang; Peng Luo
Journal:  Front Immunol       Date:  2021-03-08       Impact factor: 7.561

8.  Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.

Authors:  Xinqing Lin; Liqiang Wang; Xiaohong Xie; Yinyin Qin; Zhanhong Xie; Ming Ouyang; Chengzhi Zhou
Journal:  Front Mol Biosci       Date:  2020-11-19

9.  The immunomodulatory activities of licorice polysaccharides (Glycyrrhiza uralensis Fisch.) in CT 26 tumor-bearing mice.

Authors:  Peter Amwoga Ayeka; YuHong Bian; Peter Mwitari Githaiga; Ying Zhao
Journal:  BMC Complement Altern Med       Date:  2017-12-15       Impact factor: 3.659

10.  A robust gene signature for the prediction of early relapse in stage I-III colon cancer.

Authors:  Weixing Dai; Yaqi Li; Shaobo Mo; Yang Feng; Long Zhang; Ye Xu; Qingguo Li; Guoxiang Cai
Journal:  Mol Oncol       Date:  2018-02-16       Impact factor: 6.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.